1. Home
  2. PRTC vs PACB Comparison

PRTC vs PACB Comparison

Compare PRTC & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • PACB
  • Stock Information
  • Founded
  • PRTC 2015
  • PACB 2000
  • Country
  • PRTC United States
  • PACB United States
  • Employees
  • PRTC N/A
  • PACB N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • PACB Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PRTC Health Care
  • PACB Industrials
  • Exchange
  • PRTC Nasdaq
  • PACB Nasdaq
  • Market Cap
  • PRTC 413.5M
  • PACB 364.2M
  • IPO Year
  • PRTC N/A
  • PACB 2010
  • Fundamental
  • Price
  • PRTC $19.07
  • PACB $1.54
  • Analyst Decision
  • PRTC Buy
  • PACB Buy
  • Analyst Count
  • PRTC 1
  • PACB 9
  • Target Price
  • PRTC $45.00
  • PACB $2.06
  • AVG Volume (30 Days)
  • PRTC 3.4K
  • PACB 9.1M
  • Earning Date
  • PRTC 08-27-2025
  • PACB 08-07-2025
  • Dividend Yield
  • PRTC N/A
  • PACB N/A
  • EPS Growth
  • PRTC N/A
  • PACB N/A
  • EPS
  • PRTC 0.21
  • PACB N/A
  • Revenue
  • PRTC $4,828,000.00
  • PACB $152,357,000.00
  • Revenue This Year
  • PRTC $35.98
  • PACB $3.33
  • Revenue Next Year
  • PRTC $115.38
  • PACB $17.88
  • P/E Ratio
  • PRTC $8.64
  • PACB N/A
  • Revenue Growth
  • PRTC 44.98
  • PACB N/A
  • 52 Week Low
  • PRTC $13.30
  • PACB $0.85
  • 52 Week High
  • PRTC $25.00
  • PACB $2.72
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 57.26
  • PACB 57.34
  • Support Level
  • PRTC $18.16
  • PACB $1.35
  • Resistance Level
  • PRTC $19.60
  • PACB $1.76
  • Average True Range (ATR)
  • PRTC 0.43
  • PACB 0.11
  • MACD
  • PRTC 0.10
  • PACB 0.00
  • Stochastic Oscillator
  • PRTC 69.77
  • PACB 46.34

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Share on Social Networks: